RNA Targeted DRUG DISCOVERY : Transforming RNA-targeted DRUG DISCOVERY

MAGNA™ - Transforming RNA-targeted DRUG DISCOVERY

MAGNA™ enables confident hit-to-lead selection and optimization, accelerating and de-risking the development of novel RNA-targeted therapeutics

RNA is largely unexplored as a drug target, representing an exciting opportunity to open a new universe of life-changing therapeutics for a wide range of health conditions. However, progress in this space is hampered by a lack of effective methods to visualize and understand how RNA structures interact with candidate drugs. This major limitation can result in ineffective molecules being progressed through the drug development pipeline with consequent costly failure during late preclinical or early clinical stages.

MAGNA™ A new way to look at RNA

MAGNA™ offers a powerful new way to explore RNA-ligand interactions. Based on established magnetic force spectroscopy technology, MAGNA™ precisely measures how the biophysical properties of RNA structures change as ligands bind to them. This real-time view reveals vital information about binding kinetics and mode of action. Uniquely suited to studying the complex interactions between small molecules, proteins, and target RNAs, MAGNA™ enables confident hit-to-lead selection and optimization, accelerating and de-risking the development of novel RNA-targeted small molecule therapeutics.

Generates real-time dynamic binding measurements, providing essential pharmacodynamic information for lead optimization
Reveals whether a ligand is stabilizing or destabilizing a target RNA structure versus non-specific binding, for example to the RNA backbone
Shows how small molecules are disrupting protein-RNA interactions
Probes multi-ligand interactions, such as the effect of drug molecules on RNA-protein interactions
Simple sample preparation and analysis protocols provides accurate and reproducible data with fast turnaround time

Download e-book

See how MAGNA™ uniquely captures dynamic interactions and structural stabilization as small molecules bind to RNA:

MAGNA™ can also be used to characterize interactions between RNA and RNA binding proteins (RBPs). RBPs play a central role in regulating RNA biology and are implicated in a multitude of disorders including various cancer and neurodegenerative diseases, making them an attractive therapeutic target.